The abstract is read at the publisher; the summary is JClub's.
Loss of GDF15 in genetically engineered mouse models of pancreatic, lung, and skin cancers protects against appetite loss, muscle wasting, and fat loss, with GDF15 as the key driver.
- Why it matters: Cancer cachexia and anorexia lack effective therapies because the tumor-to-host mechanism linking immune signals to neural control of energy balance is poorly defined.
- What they did: The study used genetically engineered mouse models plus single-cell RNA sequencing to identify macrophages as a major GDF15 source, induced by tumor-derived CSF1, and tested pathway disruption with GDF15-neutralizing antibody, anti-CSF1R antibody, or a RET inhibitor.
- The result: Blocking the tumor–macrophage–GDF15–CNS feedforward loop markedly reduces both cachexia and anorexia, supporting the tumor-immune-neural triad as a therapeutic target.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.